Prophylactic sodium thiosulfate reduces the risk and severity of acute kidney injury in oxaliplatin-based hyperthermic intraperitoneal chemotherapy

Table 1 Patient characteristics, including preoperative kidney function, stratified on perioperative treatment with prophylactic sodium thiosulfate or no sodium thiosulfate, n (%)

Variable	nST (n = 73)	ST (n = 46)	P value
Age			0.731
≤ 59	31 (42)	21 (46)
> 59	42 (58)	25 (54)
Sex			0.501
Male	38 (52)	21 (46)
Female	35 (48)	25 (54)
PCI score
0-8	36 (49)	31 (67)	Reference
9-15	21 (29)	10 (22)	0.192
> 15	16 (22)	5 (11)	0.07
Baseline creatinine: Median; IQR	68 (62-80)	69 (59-76)	0.603
Baseline eGFR: Median; IQR	77 (67-86)	76 (64-87)	0.943
Preoperative kidney function4,5
G1	14 (20.3)	11 (24.4)	Reference
G2	45 (65.2)	29 (64.4)	0.672
G3a	9 (13)	3 (6.7)	0.27
G3b	1 (1.4)	2 (4.4)	0.47
Preoperative comorbidities
BMI ≥ 30	20 (27)	10 (22)	0.491
Smoking	7 (10)	5 (11)	0.82
Diabetes mellitus	10 (14)	8 (17)	0.58
Diabetes mellitus - insulin	8 (11)	1 (2)	0.20
Cardiovascular disease	9 (12)	6 (13)	0.91
Hypertension	22 (30)	18 (39)	0.31
ASA
1	28 (38)	20 (44)	Reference
2	32 (44)	19 (41)	0.652
3	13 (18)	7 (15)	0.61

¹χ² test.

²Binary logistic regression analysis.

³Mann-Whittney U test.

⁴According to Kidney Disease: Improving Global Outcomes classification of estimated glomerular filtration rate.

⁵Missing in 5 patients.

nST: No sodium thiosulfate; ST: Sodium thiosulfate; PCI: Peritoneal carcinomatosis index; IQR: Interquartile range; eGFR: Estimated glomerular filtration rate; BMI: Body mass index; ASA: American Society of Anesthesiologists.